Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month High - Here's What Happened

Key Points

• Compass Therapeutics' shares reached a new 52-week high of $4.39, closing at $4.34 with a trading volume of 588,488 shares.
• Analysts have mixed ratings on the stock, with one Strong Buy, nine Buy, and one Sell, leading to an average rating of "Moderate Buy" and a consensus price target of $13.10.
• The company reported a quarterly loss of ($0.14) EPS, slightly missing analysts' expectations, and is forecasted to post an EPS of -0.36 for the current fiscal year.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report)'s share price reached a new 52-week high on Wednesday . The company traded as high as $4.39 and last traded at $4.34, with a volume of 588488 shares trading hands. The stock had previously closed at $4.28.

Analysts Set New Price Targets

CMPX has been the subject of a number of research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. D. Boral Capital reissued a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Tuesday, August 12th. Lifesci Capital initiated coverage on shares of Compass Therapeutics in a research report on Monday, October 6th. They set an "outperform" rating and a $10.00 target price for the company. Raymond James Financial raised shares of Compass Therapeutics to an "outperform" rating and set a $9.00 target price for the company in a research report on Tuesday, July 1st. Finally, Compass Point set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $13.10.

Compass Therapeutics Stock Performance

The company has a market capitalization of $600.15 million, a PE ratio of -9.64 and a beta of 1.48. The stock's 50 day moving average is $3.41 and its 200 day moving average is $2.68.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). On average, equities research analysts forecast that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning bought a new position in shares of Compass Therapeutics in the 2nd quarter worth $30,000. Strs Ohio bought a new position in shares of Compass Therapeutics during the 1st quarter valued at $34,000. Birchview Capital LP purchased a new stake in Compass Therapeutics during the 1st quarter valued at $46,000. Walleye Trading LLC purchased a new stake in Compass Therapeutics during the 1st quarter valued at $48,000. Finally, Vontobel Holding Ltd. purchased a new stake in Compass Therapeutics during the 1st quarter valued at $57,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.